3D Tissue Models

Cancer Biology: Genentech

Total Score People Score Events Score
67 56 52
Date Event Presentation Speakers
March 2, 2015 13th International Congress on Targeted Anticancer Therapies 13th International Congress on Targeted Anticancer Therapies Priti Hegde
May 23, 2014 Cellular Signalling and Cancer Therapy Tumor Suppressor role for the deubiquitinase, BAP1 Vishva Dixit
December 17, 2013 Pharmacology 2013 The non-canonical Inflammasome Pathway Vishva Dixit
October 28, 2013 Tumor Immunology and Immunotherapy Oncology meets immunology: targeting PD-L1 in combination Ira Mellman
June 19, 2013 Molecular Diagnostics for Cancer Drug Development Phospho flow pharmacodynamic assays for clinical trials Shidong Jia
June 12, 2013 Montreal International Symposium on Angiogenesis and Metastasis – MISAM-2013 Montreal International Symposium on Angiogenesis and Metastasis – MISAM-2013 Heidi Phillips
April 6, 2013 AACR Annual Meetings Expanding the Druggable Genome Chairperson: Stephen W. Fesik, Vanderbilt University School of Medicine, Nashville, TN Domagoj Vucic
Mitotic Checkpoints Driving Cancer Therapeutic Strategies Chairperson: Peter K. Jackson, Genentech, Inc., South San Francisco, CA Peter K Jackson
March 3, 2013 Understanding Dendritic Cell Biology to Advance Disease Therapies (C2) Harnessing DC Biology to Advance Disease Therapies Ira Mellman
Translating DC Biology into Medicine Ira Mellman
February 25, 2013 4th Cancer Targets and Therapeutics Targeting Inhibitor of Apoptosis (IAP) Proteins for Anti-cancer Therapies Domagoj Vucic
Opposing Effects of Androgen Deprivation and Targeted Therapy on Prostate Cancer Prevention Shidong Jia
January 31, 2013 11th Cytokines and Inflammation Ubiquitination Regulates TNF Family Signaling Domagoj Vucic
August 24, 2012 21st Annual Short Course on Experimental Models of Human Cancer Targeting the Hedgehog pathway in cancer: From Bench to Clinic Frederic J. de Sauvage
November 29, 2011 The 7th annual European Antibody Congress is the worldleading conference addressing critical scientific issues and strategic industry challenges associated with therapeutic mAb development. Effects of molecular properties on antibody pharmacokinetics: recent lessons Saileta Prabhu
November 12, 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Concurrent Session 3 | Clinical development strategies of PI3K inhibitors Mika Derynck
March 6, 2011 Stem Cells, Cancer and Metastasis (C4) Developmental Regulatory Pathways and Cancer Drug Discovery Frederic J. de Sauvage
February 24, 2011 Targeting P13K / mTOR Signaling in Cancer Title to be announced Mark R Lackner
February 12, 2011 Cancer Control by Tumor Suppressors and Immune Effectors (J8) Dendritic Cells (J7) | MHC Class II Pathways Ira Mellman
January 13, 2011 Inaugural Antibody Drug Products Drug Conjugation Site Modulates the Stability and Biological Activity of Antibody Drug Conjugates Ben Shen
January 12, 2011 Antibodies for the 21st Century Endogenous Anti-IFNa Autoantibodies in Patients with Systemic Lupus Erythematosus are Associated with Decreased IFN-Pathway and Disease Activity Alyssa Morimoto
October 24, 2010 Frontiers in Tumour Progression Short Talk Frederic J. de Sauvage
August 23, 2010 The Ubiquitin Drug Discovery & Diagnostics Conference Enzyme regulatory mechanisms of USP7 James Ernst
May 20, 2010 Bioanalytical Challenges for Optimizing Protein Therapeutics Free vs. Total Ligand Binding Assays: Points to Consider in Drug Development Jihong Yang
Immunogenicity: Regulatory and Technical Overview with Case Studies of Assay Challenges Eric Wakshull
May 20, 2010 Revival of Bispecific Antibodies: The Way Forward? bis-Fabs: A New Platform for Bispecific Molecules Justin M. Scheer
May 19, 2010 Pre-Clinical / Clinical Development of Therapeutic Antibodies Recommendations for Nonclinical PK Comparability Study Designs for Monoclonal Antibodies Wendy Putnam
May 19, 2010 Towards Personalized Cancer Medicine Role of the Microenvironment in VEGF-Independent Angiogenesis Napoleone Ferrara
October 6, 2009 Phage Display to Develop Therapeutic Antibodies Synthetic PDZ Domains for Functional Genomics Sachdev Sidhu
Antibody Fragments and Scaffolds Sachdev Sidhu
August 26, 2009 Optimizing Mammalian Cell Lines Development of a Novel Double Selection System to Improve Antibody Productivity in CHO Cell Lines Domingos Ng
August 5, 2009 New Frontiers in Cancer Drug Development Cancer Stem Cells Chia Portera
Targeting the Hedgehog Pathway in Cancer Treatment Chia Portera
Bevacizumab in Patients with Previously Treated Glioblastoma Asha Das
August 3, 2009 The Next Wave of Antibody Therapeutics Antibody-Drug Conjugates for Cancer Therapy Paul G. Polakis
Clinical Results of the Phase I and Phase II Studies of Trastuzumab-DM1, A First-in-class HER2 Antibody-Drug Conjugate, in Patients with HER2+ Metastatic Breast Cancer Barbara Klencke
June 16, 2009 7th Annual Comparability for Biologics Selection of acceptance criteria for comparability studies throughout the development lifecycle Wassim Nashabeh
Regulatory expectations in the US for demonstrating comparability of biotechnology products Earl Dye
June 9, 2009 RNAi for Target Identification and Validation Unlocking the Genome with Pooled shRNA Screens David P. Davis
June 9, 2009 Translating Genomic Knowledge Genomic Tools in Identifying Markers of Resistance: ABCC3 Co-Amplification in HER2 Positive Breast Cancer Ajay Pandita
June 8, 2009 RNAi for Functional Screens Probing the p53 Pathway Laura Corson
June 8, 2009 The Business of Genomics Talk Title to be Announced Anna Williamson
December 1, 2008 European Antibody Congress 2008 Immunogenicity assessment of antibody therapeutics – Bioanalytical strategy and risk-based approach Patrick Liu
Keynote presentation: Trastuzumab DM1 (T-DM1): an advanced antibody-drug conjugate based on Herceptin Mark Sliwkowski
Panel discussion: assessing the market impact of domain/fragment approaches on classical antibody development Mark Sliwkowski
November 10, 2008 The Burrill Personalized Medicine Meeting Keynote Speaker: Personalized Medicine After Herceptin Susan D Desmond-Hellman
October 31, 2008 Changing Paradigms in Lung Cancer Care and Advances in the Pipeline Therapeutic Workshop Philippe Bishop
October 12, 2008 15th North American Regional Meeting - International Society for the Study of Xenobiotics Protein Metabolism/catabolism in the Disposition of Protein Therapeutics Paul J. Fielder
Optimizing ADME/PK Properties of Biotherapeutics Lisa Damico
Establishing the First in Human Dose for Biotherapeutics Jennifer E. Visich
June 18, 2008 Accelerating Anticancer Agent Development and Validation Workshop Panel Discussion David P Schenkein
Proof of Concept to the Drug Developer David P Schenkein
Panel Discussion David P Schenkein
May 30, 2008 ASCO Annual'08 Meeting professional development-- Contract Negotiations for Your First Job in Industry, Private Practice, or Academia Sean P. Bohen
April 30, 2008 Assessment of Immunogenicity in Clinical Trials Case Study –Risk-based Immunogenicity Valerie Quarmby
April 28, 2008 Clinical Development of Therapeutic Antibodies The Development of Antiangiogenics in Lung Cancer Jane Huang
April 27, 2008 Phage Display of Antibodies and Peptides Chairperson’s Remarks Dev Sidhu
Synthetic Antibodies Germaine Fuh
March 25, 2008 CYTOKINE-BASED THERAPEUTICS Preclinical Studies of Anti-OX40L in TH2-Driven Diseases Sarah Hymowitz
Title to Be Determined Vishva M. Dixit
March 2, 2008 MOLECULAR MECHANISMS IN LYMPHATIC FUNCTION & DISEASE The role of Neuropilin-2 in tumor lymphangiogenesis Anil Bagri
February 12, 2008 NF-kappaB Signaling to NF-kappaB Vishva M. Dixit
February 10, 2008 GRC - Plasminogen Activation & Extracellular Proteolysis The transmembrane serine protease hepsin activates pro-hepatocyte growth factor (HGF) and pro-urokinase plasminogen activator (uPA) and promotes tumor progression Daniel Kirchhofer
November 12, 2007 Well Characterized Biologicals - Continuous Evolution of Chemo- and Bioanalytical Approaches Nov(12 - 14) Analysis of Protein Glycosylation (10:45-13:25) An Song
Analysis of Protein Glycosylation:Anticipating Effects of Glycosylation on Effector Functions (10:45-11:15) An Song
Causes and Assessment of Product and Process-Related Impurities (13:25-18:30) Fred Jacobson
Causes and Assessment of Product and Process-Related Impurities:Protein Aggregation and Bioprocessing (13:30-14:00) Fred Jacobson
Early Formulation Development (08:15-09:15) Jim Andya
Early Formulation Development: Early Development Screening of Monoclonal Antibody Formulations (08:15-08:45) Jim Andya
Process and Analytical Related Issues (15:30-17:00) Ron Taticek
Process and Analytical Related Issues: Quality by Design in the Development of Post-Approval Changes for Cell Culture Processes (15:30-16:00) Ron Taticek
November 7, 2007 Antibodies Europe: Engineering the Next Generation of Antibodies Nov (07-08) Engineering Therapeutics (10:00-11:30) Robert Kelley
Engineering Therapeutics: Fc Engineering of Therapeutic Antibodies (10:00-10:30) Robert Kelley
November 7, 2007 Srial II: Advances and Challenges Toward Major Diseases: Extension on New Hope Nov (07-13) Session 7: Anti-Cancer/Tumors Drug Discovery & Development and Current Status of the Innovative Therapeutics (Part II) (09:00-12:00) Mark S. Dennis
Session 7: Tumor Targeting with an AB.Fab (09:00-09:20) Mark S. Dennis
October 1, 2007 Barcelona BioMed Conferences: STEM CELLS AND CANCER Session IV: Cancer stem cells - I (14:30-18:20) Erica Jackson
Session IV: Cancer stem cells - I (16:50 -17:10) Erica Jackson
August 11, 2007 Growth factor receptor tyrosine kinases in mitogenesis, morphogenesis Signaling specificity of growth factor RTKs (2nd part) Mark Sliwkowski
HER2 activation in breast and ovarian cancers Mark Sliwkowski
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.